# BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Subsidiary Publishes Landmark Primer on Oncology Real-World Evidence

Fifty 1 Labs (OTC: FITY) through its subsidiary Fifty1 AI Labs, announced the publication of a landmark technical primer on transportability methods in oncology real-world evidence (RWE) in the Journal of Comparative Effectiveness Research. Co-authored by CTO Alind Gupta and CEO Paul Arora, the paper showcases how advanced statistical and AI-driven frameworks can bridge data gaps, accelerate health technology assessments, and improve global access to life-saving therapies. With the oncology RWE market projected to expand from $789 million in 2024 to $3.51 billion by 2035 at a CAGR of 14.7%, the publication underscores Fifty1 Labs’ leadership in advancing drug repurposing and treatment access, particularly in rare diseases and underserved regions.

 To view the full press release, visit https://ibn.fm/NvQCN

 About Fifty1 AI Labs

 Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: FITY), is redefining drug discovery by using AI to unlock new potential in proven medicines. By repurposing safe, off-patent compounds, we accelerate smarter therapies that improve lives, reduce costs, and create lasting value for patients, partners, and forward-thinking investors.

 For more information, visit the company’s website at https://fifty1labs.com/

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-fifty-1-labs-inc-otc-fity-subsidiary-publishes-landmark-primer-on-oncology-real-world-evidence/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/fifty1-labs-publishes-landmark-ai-research-transforming-oncology-treatment-access/cdc4c18f11efb78f4eea85af762d3b09) 

 



[Reddit Post](https://www.reddit.com/r/newsramp/comments/1n8c1f3/fifty1_labs_publishes_landmark_ai_research/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/259/4/tilesZYA.webp)